IBIO Key Statistics, Chart & Performance
The current stock price of IBIO is 2.41 USD. In the past month the price decreased by -10.74%. In the past year, price decreased by -29.74%.
IBIO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to IBIO. When comparing the yearly performance of all stocks, IBIO is one of the better performing stocks in the market, outperforming 90.11% of all stocks.
IBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IBIO. Both the profitability and financial health of IBIO have multiple concerns.
IBIO Financial Highlights
Over the last trailing twelve months IBIO reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS increased by 73.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.26% | ||
| ROE | -123.5% | ||
| Debt/Equity | 0.05 |
IBIO Forecast & Estimates
10 analysts have analysed IBIO and the average price target is 4.61 USD. This implies a price increase of 91.3% is expected in the next year compared to the current price of 2.41.
For the next year, analysts expect an EPS growth of 81.54% and a revenue growth -25% for IBIO
IBIO Ownership
IBIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.37 | 394.886B | ||
| AMGN | AMGEN INC | 16.68 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.01 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.74 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.62 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IBIO
Company Profile
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Company Info
IBIO INC
11750 Sorrento Valley Road, Suite 200
San Diego CALIFORNIA 77807 US
CEO: Thomas F. Isett
Employees: 20
Phone: 19794460027
IBIO INC / IBIO FAQ
What does IBIO INC do?
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
What is the current price of IBIO stock?
The current stock price of IBIO is 2.41 USD. The price decreased by -0.41% in the last trading session.
What is the dividend status of IBIO INC?
IBIO does not pay a dividend.
How is the ChartMill rating for IBIO INC?
IBIO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for IBIO INC?
IBIO INC (IBIO) operates in the Health Care sector and the Biotechnology industry.
Would investing in IBIO INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IBIO.
What is the market capitalization of IBIO stock?
IBIO INC (IBIO) has a market capitalization of 54.20M USD. This makes IBIO a Micro Cap stock.